• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·ETBI
Share

Eastgate Biotech Corp. Stocks

$ 0.01Last Updated 22.10.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

$ 10.29M

$ 0.01
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

EastGate Biotech Corp. is a pharmaceutical company specializing in the production and distribution of nutraceuticals. These products are rooted in natural therapies and designed for natural absorption within the body. The firm employs cutting-edge nanotechnologies to provide healthier options compared to conventional pharmaceuticals, which often lead to detrimental side effects and unforeseen issues for individuals seeking to achieve and maintain good health. Among its diverse product line are E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze, and Warts X. EastGate Biotech's development process involves integrating product components into various nano-sized delivery systems. These systems include oil droplets (nanoemulsions), polymeric particles (nanoparticles), and complex combinations of polymers, lipids, and surfactants (such as hybrid nanoparticles, nanocapsules, and mixed micelles). The company has operational bases in prominent cities including New York, London SF, Cockfosters BP, Los Angeles, Chicago, and Las Vegas.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 00:38

Microsoft is cutting costs: 60,000 employees have been offered voluntary separation

27.10.2026 00:18

"If the bubble bursts, it will all start with debt": How the problems of the neo-claws threaten the S&P 500

26.10.2026 23:40

Buyers of the foldable iPhone have complained about screen damage. How does this affect the stock price?

26.10.2026 23:02

One of Wall Street’s biggest bulls drops overweight call on stocks ahead of midterms

26.10.2026 22:15

Revolut launches personal loans in the UK. What does this mean for the neobank?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026